Xpert® C. difficile BT
Detection of Clostridium difficile in Around 45 Minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Collection devices
product image
Single Use Disposable Swab (Pack of 120)
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

C. difficile infections (CDI) have been increasing in incidence and severity, and are associated with an increase in length of hospital stay, costs, morbidity and mortality.2
  • Highly virulent (027-NAP1-BI) strains have caused outbreaks of severe disease in Europe and North America3
  • Binary toxin (BT) may be important because of:
    • Links to both disease severity and outcome4
    • Strains such as 033 are positive only for binary toxin and not toxins A and B, yet have caused CDI5,6
Incremental costs associated with C. difficile infection7
(2) European Hospital and Healthcare Federation (HOPE). CDI Europe Report, 2013: Clostridium difficile infection in Europe. FDX/12/0082/EU.(3) Marujo V, et al. The largely unnoticed spread of Clostridioides difficile PCR ribotype 027 in Germany after 2010. IPIP. 2020 Dec;2(4):100102.(4) Stewart D, et al. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastrointest Surg. 2013 Jan;17(1):118-24.(5) Eckert C, et al. Prevalence and pathogenicity of binary toxin-positive C. difficile strains that do not produce toxins A and B. New Microbes New Infect. 2014 Nov;8(3):12-7.(6) Androga G, et al. Evaluation of the Cepheid Xpert C. difficile/Epi and meridian bioscience illumigene C. difficile assays for detecting Clostridium difficile ribotype 033 strains. J Clin Microbiol. 2015 Mar;53(3):973-5.(7) Tresman R & Goldenberg S. Healthcare resource use and attributable cost of Clostridium difficile infection: a micro-costing analysis comparing first and recurrent episodes. J Antimicrob Chemother. 2018 Oct;73(10):2851-2855.

The Solution

CDI has become a substantive and growing burden in hospitalised patients prompting the need for earlier and accurate detection.
Xpert® C. difficile BT enables:
  • Fast identification of toxin-producing C. difficile in around 45 minutes
  • Broad coverage with multiple targets, including: toxin B (tcdB), binary toxin (cdtA), and the tcdC deletion at base 117 associated with the ribotype 027 strain, a predictor of severe CDI and mortality8
  • Optimised and prompt administering of therapy to support improved patient outcomes9
  • Timely infection control initiatives to reduce the spread of infection10
  • Laboratory efficiencies with on-demand workflows requiring minimal hands-on time and no repeat testing1,11
(1) Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).(8) Rao K, et al. C. difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015 Jul 15;61(2):233-41.(9) Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):693-43.(10) Schroeder L, et al. Economic evaluation of laboratory testing strategies for hospital-associated Clostridium difficile infection. JCM. 2014 Feb;52(2):489.(11) Following C. difficile sampling guidance detailed in: McDonald L, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Apr;66(7):e1–e48.CATALOG INFORMATION Xpert® C. difficile BT10 tests GXCDIFFBT-CE-10

The Impact

On-demand answers, anywhere and anytime your patients need care